There are only two drugs approved for the treatment of IPF in the United States. One is Esbriet (pirfenidone) and the other is OFEV (nintedanib). Esbriet requires a dosage escalation over a couple of weeks before settling down to three doses a day. OFEV is two doses daily at the same time each day. Both drugs are very expensive. You might ask your doctor why he prescribes one drug over the other.
This is a good question, although I don’t believe there are any drugs available test to test the effectiveness of ‘curing’ / stoping COVID-19. I don’t believe, but I could be wrong. Likely PF patient’s can’t try it because of possible drug interactions with our anti-fibrotics, which Ross listed above (thank you @cimarronkid ) or we have another dangerous co-morbidity/disease that could alter the effectiveness of the drug in those who are healthy. These are all just guesses of course, but I suspect they will be wanting to test it in the most optimal population, which are those who are healthy. Hope you’re keeping as well as possible.
Pulmonary Fibrosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.